3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Adenosarcoma of the uterus
1
Interventions
Radiosurgery
9
Temozolomide
8
Magnetic Resonance Spectroscopy
5
pembrolizumab
4
Specimen Handling
4
Nivolumab
4
Bevacizumab
4
Receptors, Interleukin-8B
3
Memantine
3
trastuzumab deruxtecan
2
abemaciclib
2
Watchful Waiting
2
Surveys and Questionnaires
2
Radiotherapy
2
Radiation
2
Mental Status and Dementia Tests
2
Ipilimumab
2
Biopsy
2
sotorasib
1
sapanisertib
1
sacituzumab govitecan
1
ribociclib
1
pertuzumab
1
osimertinib
1
lenvatinib
1
fluciclovine F-18
1
entrectinib
1
elacestrant
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
RAD1901
×
30 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled